New combo therapy shows promise for rare bone marrow cancer
NCT ID NCT02251821
First seen Dec 11, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study looked at whether giving a JAK inhibitor drug before a donor stem cell transplant helps people with myelofibrosis, a serious bone marrow disorder. 61 patients received the drug ruxolitinib before their transplant. The goal was to improve survival and reduce complications like graft-versus-host disease. The study measured how many patients survived for 2 years after the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.